Literature DB >> 6611220

Comparison of late changes in internal mammary artery and saphenous vein grafts in two consecutive series of patients 10 years after operation.

C M Grondin, L Campeau, J Lespérance, M Enjalbert, M G Bourassa.   

Abstract

Postoperative angiographic studies were carried out at 1 month, 1 year, and 10 years in two groups of patients: 238 patients with saphenous vein (SV) grafts and 40 patients with internal mammary artery (IMA) grafts. Cumulative patency was better in IMA grafts, both at 1 year (88.5% vs 76.4%) and at 10 years (84.1% vs 52.8%). Atheromatous changes in patent grafts at 10 years were frequent in SV grafts (29/66 or 43.9%) and uncommon in IMA grafts (1/19 or 5.2%; p less than .02). Attrition rate (11.8%) during the first year in IMA grafts (representing our initial experience with IMA grafts) was comparable to that of SV grafts (15.2%) in a group of patients operated on after 2 years of experience. Therefore, early attrition rate may be related to both experience and type of conduit. Later, at 10 years, the conduit itself appears to be the dominant factor. Furthermore, patients who received IMA grafts had a better survival rate at 10 years (84.3% vs 70%) than those who underwent SV bypass grafting.

Entities:  

Mesh:

Year:  1984        PMID: 6611220

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  36 in total

1.  Coronary artery bypass grafting. Late result of actual 10-years follow-up in 376 patients.

Authors:  K Takazawa; Y Hosoda; T Yamamoto; S Kawasaki; S Sasaguri
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1999-03

2.  Diagnostic accuracy of 64-slice multidetector computed tomography in evaluation of post-coronary artery bypass grafts in correlation with invasive coronary angiography.

Authors:  Rajani Gorantla; J S N Murthy; T R Muralidharan; Rupesh Mandava; Bhawna Dev; Harsha Chandaga; R Rajeswaran; J D Roy Santosham; Santhosh Joseph
Journal:  Indian Heart J       Date:  2012 May-Jun

Review 3.  The comparative efficacy of percutaneous and surgical coronary revascularization in 2009: a review.

Authors:  Stephen A May; James M Wilson
Journal:  Tex Heart Inst J       Date:  2009

4.  The improving outcomes of coronary artery bypass graft surgery in Ontario, 1981 to 1995.

Authors:  J V Tu; K Wu
Journal:  CMAJ       Date:  1998-08-11       Impact factor: 8.262

5.  Long-term benefits of internal thoracic artery-coronary artery bypass in Japanese patients.

Authors:  S Kitamura; K Kawachi; S Taniguchi; T Kawata; S Kobayashi; H Nishioka; K Mizuguchi; K Niwaya; Y Kameda; H Sakaguchi
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1998-01

6.  Saphenous vein graft failure after coronary artery bypass surgery: insights from PREVENT IV.

Authors:  Connie N Hess; Renato D Lopes; C Michael Gibson; Rebecca Hager; Daniel M Wojdyla; Brian R Englum; Michael J Mack; Robert M Califf; Nicholas T Kouchoukos; Eric D Peterson; John H Alexander
Journal:  Circulation       Date:  2014-09-26       Impact factor: 29.690

7.  Pulmonary function tests after different techniques for coronary artery bypass surgery. Saphenous vein versus single versus double internal mammary artery grafts.

Authors:  P G Ferdinande; G Beets; A Michels; E Lesaffre; P Lauwers
Journal:  Intensive Care Med       Date:  1988       Impact factor: 17.440

8.  [Clinical evaluation of right gastroepiploic artery (RGEA) graft--comparison of RGEA with right internal thoracic artery (RITA) graft in the coronary bypass grafting (CABG) operation using only arterial grafts].

Authors:  S Hayashi; M Sasaki; J Kawamoto; Y Kawaue
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1998-06

9.  Congenital internal mammary artery-to-pulmonary artery fistulas: a case report.

Authors:  Y Yamada; H Imamura; Y Amamoto; M Ochi; K Nagano; M Ito
Journal:  Heart Vessels       Date:  1987       Impact factor: 2.037

Review 10.  Coronary vein graft disease: pathogenesis and prevention.

Authors:  Pirouz Parang; Rohit Arora
Journal:  Can J Cardiol       Date:  2009-02       Impact factor: 5.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.